{"nctId":"NCT03803475","briefTitle":"Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients","startDateStruct":{"date":"2018-10-11","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":485,"armGroups":[{"label":"Ga-68 labeled PSMA-11 PET PSMA","type":"EXPERIMENTAL","interventionNames":["Drug: Ga-68 labeled PSMA-11","Device: Positron emission tomography-computed tomography (PET/CT)","Device: Positron emission tomography-magnetic resonance imaging (PET/MRI)"]}],"interventions":[{"name":"Ga-68 labeled PSMA-11","otherNames":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED- CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"]},{"name":"Positron emission tomography-computed tomography (PET/CT)","otherNames":["PET-CT"]},{"name":"Positron emission tomography-magnetic resonance imaging (PET/MRI)","otherNames":["PET-MRI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male, age \\>= 18.\n2. Histopathologically proven prostate adenocarcinoma.\n3. Concern for metastatic disease in one of the following settings:\n\n   1. Initial staging with intermediate to high risk prostate cancer.\n   2. Biochemical recurrence after initial therapy.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1\\. Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group","description":"Detection rate is defined as the proportion of all patients who have prostate cancer and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null}]}]}]},{"type":"PRIMARY","title":"Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group","description":"Detection rate is defined as the proportion of all patients who have prostate cancer located in the prostate bed and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null}]}]}]},{"type":"PRIMARY","title":"Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group","description":"Detection rate is defined as the proportion of all patients who have prostate cancer located in the pelvic nodes and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null}]}]}]},{"type":"PRIMARY","title":"Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group","description":"Detection rate is defined as the proportion of all patients who have prostate cancer located in the distant soft tissues and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null}]}]}]},{"type":"PRIMARY","title":"Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group","description":"Detection rate is defined as the proportion of all patients who have prostate cancer located in the bone (osseous lesions) and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":485},"commonTop":[]}}}